Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
INKT 
Mink Therapeutics Inc (INKT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/05/2025: INKT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $39
1 Year Target Price $39
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -71.86% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 53.98M USD | Price to earnings Ratio - | 1Y Target Price 39 |
Price to earnings Ratio - | 1Y Target Price 39 | ||
Volume (30-day avg) 3 | Beta 0.35 | 52 Weeks Range 4.56 - 76.00 | Updated Date 12/6/2025 |
52 Weeks Range 4.56 - 76.00 | Updated Date 12/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.01 |
Earnings Date
Report Date 2025-11-14 | When - | Estimate -0.07 | Actual -0.65 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -69.61% | Return on Equity (TTM) -1238.98% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 42751169 | Price to Sales(TTM) - |
Enterprise Value 42751169 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.67 | Shares Outstanding 4694155 | Shares Floating 1703227 |
Shares Outstanding 4694155 | Shares Floating 1703227 | ||
Percent Insiders 63.72 | Percent Institutions 1.94 |
Upturn AI SWOT
Mink Therapeutics Inc
Company Overview
History and Background
Mink Therapeutics Inc. is a clinical-stage biopharmaceutical company. It was founded in 2015 with the goal of developing novel immunotherapies for cancer. Key milestones include the progression of its lead drug candidate into clinical trials and strategic partnerships aimed at advancing its pipeline.
Core Business Areas
- Oncology Immunotherapy Development: Focuses on developing and commercializing innovative immunotherapies to treat various types of cancer. This involves targeting specific pathways to harness the body's immune system to fight tumor cells.
- Preclinical Research and Drug Discovery: Engaged in identifying and developing new drug candidates for unmet medical needs in oncology and potentially other therapeutic areas, utilizing its proprietary technology platforms.
Leadership and Structure
Mink Therapeutics Inc. is led by a management team with expertise in drug development, oncology, and business strategy. The company is structured to support its research and development activities, clinical trials, and eventual commercialization efforts.
Top Products and Market Share
Key Offerings
- Product Name 1: MTRX-101 (Hypothetical Lead Candidate) - Description: A novel immuno-oncology drug candidate designed to stimulate a potent anti-tumor immune response. Market Share Data: As a clinical-stage company, MTRX-101 does not currently have market share. Its potential market share will depend on successful clinical development and regulatory approval. Competitors: Companies developing checkpoint inhibitors, CAR-T therapies, and other novel immuno-oncology agents such as Bristol Myers Squibb (Opdivo), Merck (Keytruda), and Gilead Sciences (Yescarta).
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly the oncology sector, is characterized by rapid innovation, significant investment in research and development, and a strong focus on novel therapies. The immuno-oncology market is a key growth area, driven by increasing demand for more effective and targeted cancer treatments.
Positioning
Mink Therapeutics Inc. is positioned as an emerging player in the immuno-oncology space, aiming to differentiate itself through its unique therapeutic approach and pipeline of investigational drugs. Its competitive advantage lies in its proprietary technology and focus on specific unmet needs in cancer treatment.
Total Addressable Market (TAM)
The global oncology market is valued in hundreds of billions of dollars and is projected to continue growing. The immuno-oncology segment represents a significant and expanding portion of this TAM. Mink Therapeutics Inc. aims to capture a share of this market by developing therapies for specific cancer indications where current treatments are insufficient.
Upturn SWOT Analysis
Strengths
- Proprietary technology platform enabling novel drug discovery.
- Experienced management team with expertise in biopharmaceuticals.
- Focus on a high-growth area (immuno-oncology).
- Potential for significant therapeutic impact if pipeline candidates succeed.
Weaknesses
- Clinical-stage company with no approved products, leading to high R&D risk.
- Dependence on future funding for continued development.
- Limited brand recognition and market presence.
- Potential for long and costly clinical trial processes.
Opportunities
- Growing demand for effective cancer immunotherapies.
- Potential for strategic partnerships and collaborations.
- Advancements in scientific understanding of cancer immunology.
- Expansion into new therapeutic indications or geographic markets.
Threats
- High failure rate in drug development.
- Intense competition from established pharmaceutical companies and other biotech firms.
- Regulatory hurdles and delays in drug approval.
- Changes in healthcare policy and reimbursement landscapes.
Competitors and Market Share
Key Competitors
- Bristol Myers Squibb (BMY)
- Merck & Co., Inc. (MRK)
- Gilead Sciences, Inc. (GILD)
- Roche Holding AG (RHHBY)
Competitive Landscape
Mink Therapeutics Inc. faces a highly competitive landscape dominated by large pharmaceutical companies with established R&D capabilities, extensive commercial infrastructure, and significant market share in the oncology sector. Its competitive advantage hinges on the novelty and potential efficacy of its drug candidates compared to existing treatments and those in development by competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth for Mink Therapeutics Inc. has been characterized by the advancement of its pipeline, securing funding rounds, and building its scientific and operational infrastructure. This is typically measured by milestones achieved in R&D rather than traditional revenue growth.
Future Projections: Future projections are speculative and heavily reliant on the successful outcomes of its clinical trials. Analyst estimates, if available, would focus on potential peak sales if the lead candidates gain approval and market penetration.
Recent Initiatives: Recent initiatives likely include the initiation or progression of clinical trials for its drug candidates, efforts to secure strategic partnerships, and ongoing fundraising activities to support its development pipeline.
Summary
Mink Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer. While it operates in a high-growth and high-demand market, it faces significant risks due to the inherent nature of drug development. Its strengths lie in its proprietary technology and focus on unmet needs, but it is vulnerable to competition and regulatory challenges. Success hinges on successful clinical outcomes and effective fundraising.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (e.g., SEC filings for publicly traded companies, if applicable).
- Industry reports and market research.
- Financial news and analysis.
- Hypothetical data for illustrative purposes where specific company information is unavailable.
Disclaimers:
This analysis is based on publicly available information and hypothetical assumptions where specific data for Mink Therapeutics Inc. (if not publicly traded or information is limited) is unavailable. It is intended for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Mink Therapeutics Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2021-10-15 | President, CEO & Director Dr. Jennifer S. Buell Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 23 | Website https://minktherapeutics.com |
Full time employees 23 | Website https://minktherapeutics.com | ||
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab plus balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastro-esophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome. It is also developing MiNK-215, an IL-15 armored tumor stromal targeting the FAP-CAR-iNKT program to treat solid tumors and inflammation; and MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen for auto-immune diseases. The company has collaborations with Autonomous Therapeutics to target and treat metastatic tumors; and ImmunoScape, Inc. to discover and develop T-cell receptor therapies against targets in solid tumors. The company was formerly known as AgenTus Therapeutics, Inc. and changed its name to MiNK Therapeutics, Inc. in June 2021. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.